EMCOR Group Inc (EME)vsVertex Pharmaceuticals Inc (VRTX)
EME
EMCOR Group Inc
$817.44
-3.31%
INDUSTRIALS · Cap: $36.65B
VRTX
Vertex Pharmaceuticals Inc
$446.83
-1.60%
HEALTHCARE · Cap: $114.33B
Smart Verdict
WallStSmart Research — data-driven comparison
EMCOR Group Inc generates 45% more annual revenue ($17.75B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 7.5%. EME appears more attractively valued with a PEG of 0.44. VRTX earns a higher WallStSmart Score of 68/100 (B-).
EME
Strong Buy66
out of 100
Grade: B-
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EME.
Margin of Safety
+52.4%
Fair Value
$949.55
Current Price
$446.83
$502.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 35 in profit
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
19.7% revenue growth
Earnings expanding 30.0% YoY
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Moderate valuation
Trading at 9.4x book value
7.5% margin — thin
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EME
The strongest argument for EME centers on PEG Ratio, Return on Equity, Altman Z-Score. Revenue growth of 19.7% demonstrates continued momentum. PEG of 0.44 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : EME
The primary concerns for EME are P/E Ratio, Price/Book, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
EME profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
EME carries more volatility with a beta of 1.12 — expect wider price swings.
EME is growing revenue faster at 19.7% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 66/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
EMCOR Group Inc
INDUSTRIALS · ENGINEERING & CONSTRUCTION · USA
EMCOR Group, Inc. provides electrical and mechanical installation and construction services in the United States. The company is headquartered in Norwalk, Connecticut.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other ENGINEERING & CONSTRUCTION Stocks
Want to dig deeper into these stocks?